Abstract
Background
Delayed or missed doses are inevitable in epilepsy pharmacotherapy. The current remedial measures recommended by the United States Food and Drug Administration (FDA) for non-adherence are generic and lack clinical evidence.
Aim
To assess remedial strategies for delayed or missed pregabalin doses in patients with epilepsy using Monte Carlo simulations.
Method
Monte Carlo simulations were performed using a published population pharmacokinetic model for pregabalin. The applicability of five proposed remedial regimens as well as FDA recommendations was evaluated by simulating various poor adherence scenarios in eight populations, including those with renal dysfunction.
Results
All proposed remedial strategies were associated with delay duration and renal function. When delays are relatively short, an immediate regular dose is advised. The cut-off time points for taking the regular dose as a remedial regimen were 1, 2, 4, and 12 h for patients with mild renal impairment and normal renal function, moderate renal impairment, severe renal impairment, and end-stage renal disease, respectively. However, when delay aligns closely with a dosing interval, a regular dose combined with a partial dose proves effective. Generally, supplementing 1.3-fold the regular dose at the next scheduled time adequately compensates for the missed dose.
Conclusion
Model-based simulations provided quantitative evidence for the effectiveness and feasibility of remedial strategies for missed or delayed pregabalin doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chew M, Ma G, Xie R, et al. Population pharmacokinetics of pregabalin extended-release in healthy volunteers and patients with postherpetic neuralgia, fibromyalgia, and partial-onset seizures. J Clin Pharmacol. 2019;59:1527–42. https://doi.org/10.1002/jcph.1450.
Chan PLS, Marshall SF, McFadyen L, et al. Pregabalin population pharmacokinetic and exposure-response analyses for focal onset seizures in children (4–16 years) and adults, to support dose recommendations in children. Clin Pharmacol Ther. 2021;110:132–40. https://doi.org/10.1002/cpt.2132.
Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013;9:105–15. https://doi.org/10.1517/17425255.2013.749239.
Fong JK, Chan EL, Leung H, et al. An update of the Hong Kong epilepsy guideline: consensus statement on the use of antiepileptic drugs in Hong Kong. Hong Kong Med J. 2017;23:74–88. https://doi.org/10.12809/hkmj166027.
Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012;11:487–502. https://doi.org/10.1517/14740338.2012.677026.
Antinew J, Pitrosky B, Knapp L, et al. Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: a randomized controlled trial. J Child Neurol. 2019;34:248–55. https://doi.org/10.1177/0883073818821035.
Ishida JH, McCulloch CE, Steinman MA, et al. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29:1970–8. https://doi.org/10.1681/ASN.2018010096.
Morano A, Palleria C, Citraro R, et al. Immediate and controlled-release pregabalin for the treatment of epilepsy. Expert Rev Neurother. 2019;19:1167–77. https://doi.org/10.1080/14737175.2019.1681265.
Kleinman NL, Sadosky A, Seid J, et al. Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. Epilepsy Res. 2012;102:13–22. https://doi.org/10.1016/j.eplepsyres.2012.04.019.
O’ Rourke G, O’ Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017;45:160–8. https://doi.org/10.1016/j.seizure.2016.12.006.
Wang CY, Jiao Z, Ding JJ, et al. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations. Epilepsy Behav. 2020;111: 107265. https://doi.org/10.1016/j.yebeh.2020.107265.
Malek N, Heath CA, Greene J. A review of medication adherence in people with epilepsy. Acta Neurol Scand. 2017;135:507–15. https://doi.org/10.1111/ane.12703.
Farrukh MJ, Makmor-Bakry M, Hatah E, et al. Impact of complementary and alternative medicines on antiepileptic medication adherence among epilepsy patients. BMC Complement Med Ther. 2021;21:50. https://doi.org/10.1186/s12906-021-03224-2.
Lee YK, Ah YM, Choi YJ, et al. Antiepileptic drug adherence and persistence in children with epilepsy attending a large tertiary care children’s hospital. Epileptic Disord. 2016;18:408–17. https://doi.org/10.1684/epd.2016.0871.
Brodtkorb E, Samsonsen C, Sund JK, et al. Treatment non-adherence in pseudo-refractory epilepsy. Epilepsy Res. 2016;122:1–6. https://doi.org/10.1016/j.eplepsyres.2016.02.001.
Albassam A, Hughes DA. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. Eur J Clin Pharmacol. 2021;77:251–60. https://doi.org/10.1007/s00228-020-03003-x.
Brittain ST, Wheless JW. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Epilepsy Behav. 2015;52:31–6. https://doi.org/10.1016/j.yebeh.2015.08.029.
Yu EQ, Jiao Z, Wang CY, et al. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. Epilepsy Behav. 2019;96:132–40. https://doi.org/10.1016/j.yebeh.2019.04.007.
Ding JJ, Zhang YJ, Jiao Z, et al. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation. Acta Pharmacol Sin. 2012;33:1431–40. https://doi.org/10.1038/aps.2012.135.
Li ZR, Wang CY, Lin WW, et al. Handling delayed or missed dose of antiseizure medications: a model-informed individual remedial dosing. Neurology. 2023;100:e921–31. https://doi.org/10.1212/WNL.0000000000201604.
Yin YW, Liu XQ, Gu JQ, et al. How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy. Br J Clin Pharmacol. 2023;89:2066–75. https://doi.org/10.1111/bcp.15316.
National Library of Medicine. LYRICA- pregabalin capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=124176c7-d8ab-4bbe-b468-3e5d12f03e44. Accessed 15 Mar 2023
Fryar CD, Carroll MD, Gu Q, et al. Anthropometric reference data for children and adults: United States, 2015–2018. Vital Health Stat. 2021;3(36):1–44.
Reimers A, Berg JA, Burns ML, et al. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Dev Ther. 2018;12:271–80. https://doi.org/10.2147/DDDT.S154388.
Acknowledgements
The authors thank Editage (editage. cn) for English language editing.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xie, H., Zheng, Y., Wang, C. et al. Managing delayed or missed pregabalin doses in patients with focal epilepsy: a Monte Carlo simulation study. Int J Clin Pharm 46, 150–157 (2024). https://doi.org/10.1007/s11096-023-01657-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-023-01657-y